Journal profile · Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
Therapeutics and Clinical Risk Management
ISSN 1176-6336 · eISSN 1178-203X · Dove Medical Press · New Zealand
Therapeutics and Clinical Risk Management: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.58; fully open access; APC about USD 3,940; median 107 days to acceptance (101 articles, last 24 months); 162 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Therapeutics and Clinical Risk Management is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Asthma and respiratory diseases, Anesthesia and Sedative Agents and Anesthesia and Pain Management, together about 16.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Professor Garry Walsh Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal does not accept study protocols, animal-based or cell line-based studies. Case reports/series submitted to Therapeutics and Clinical Risk Management will be diverted to the International Medical Case Reports Journal (Journal metric data for this journal can be accessed here). When considering submission of a paper utilizing publicly available data (e.g. SEER), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an original sample and functional follow-up. All meta-analyses require a pre-submission check prior to submitting to Therapeutics and Clinical Risk Management. Please complete the pre-submission check form here. All single centre retrospective studies are now out of scope for Therapeutics and Clinical Risk Management. Updated 16 December 2025
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
Editor-in-chief Walsh Emeritus ReaderPublisher website
Editorial board by country: 5 in mainland China (about 14%); most named United States 7, Italy 6, Mainland China 5, United Kingdom 2, Spain 2 (35 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Asthma and respiratory diseasesMedicine6.2%
- Anesthesia and Sedative AgentsMedicine5.5%
- Anesthesia and Pain ManagementMedicine4.8%
- Bone health and osteoporosis researchMedicine4.7%
- Sepsis Diagnosis and TreatmentMedicine4.6%
- Enhanced Recovery After SurgeryMedicine4.6%
- Venous Thromboembolism Diagnosis and ManagementMedicine4.2%
- Pharmaceutical Practices and Patient OutcomesMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Health Care Sciences & Services | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Health Care Sciences & Services | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Health Care Sciences & Services | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.58LetPub ·
- CiteScore 2026-06
- 3.7LetPub ·
- SJR 2026-06
- 0.73LetPub ·
- SJR (publisher)
- 1Publisher website ·
- SNIP 2026-06
- 1.04LetPub ·
- h-index
- 43LetPub ·
- h-index
- 91OpenAlex ·
- i10-index
- 1,431OpenAlex ·
- 2-year mean citedness
- 2.22OpenAlex ·
- Self-citation rate
- 3.8%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 154LetPub ·
Articles by year OpenAlex count · 2,513 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 72 | 72 | 14 |
| 2025 | 162 | 162 | 322 |
| 2024 | 86 | 86 | 374 |
| 2023 | 91 | 91 | 869 |
| 2022 | 104 | 104 | 1,064 |
| 2021 | 134 | 134 | 2,194 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
107 daysMedian, submission to acceptance · P25–P75 81 days – 142 days
- Acceptance to online
- median 18 days (101 articles)
- Submission to online
- median 126 days
- Sample
- 101 articles with submission and acceptance dates (255 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,940 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,836 | — | — | |
| LetPub | USD 3,300 | Yes | — | |
| Publisher website | USD 3,106 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePeer review
- Peer review
Case reports considered if valuable and original; no meta-analyses since 18 March 2019; no study protocols, animal-based or cell line-based studies. Model summary
The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- New Zealand
- Language
- English
- ISSN
- 1176-6336
- Electronic ISSN
- 1178-203X
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Therapeutics and Clinical Risk Management
What CAS zone is Therapeutics and Clinical Risk Management in?
In the 2025 upgraded edition of the CAS Journal Ranking, Therapeutics and Clinical Risk Management is in Zone 3 of Medicine, and in Zone 4 of the minor category Health Care Sciences & Services. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Therapeutics and Clinical Risk Management?
The latest impact factor listed by LetPub is 2.58; CiteScore 3.7, h-index 91.
How long does peer review take at Therapeutics and Clinical Risk Management?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 107 days (interquartile range 81–142 days); authors report an average review time of about 16 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Therapeutics and Clinical Risk Management based?
Of the 35 board members whose country the journal's board page names, 5 (about 14%) are in mainland China; the countries named most often are United States (7), Italy (6) and Mainland China (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Therapeutics and Clinical Risk Management?
According to LetPub and DOAJ records, Therapeutics and Clinical Risk Management is indexed in SCIE, Scopus and DOAJ.
Is Therapeutics and Clinical Risk Management open access, and what is the APC?
Therapeutics and Clinical Risk Management is a fully open-access journal. APC about USD 3,940.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .